CliffBio
small molecule

TYGACIL

TIGECYCLINE

Loss of exclusivityOctober 2030latest FDA-listed patent expiry
CompanyPF PRISM CV

Drug detail

Brand nameTYGACIL
Active ingredientTIGECYCLINE
Strength50MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJune 2005
Marketing statusRX

Listed patents

PatentExpiresType
8372995October 2030product
7879828February 2029product
8975242October 2028product
9254328March 2026product
9694078March 2026product
10588975March 2026product

More from PF PRISM CV

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TYGACIL patent cliff — loss of exclusivity October 2030 | CliffBio